African-American lung cancer patients with EGFR mutation respond easier to erlotinib therapy African-American patients with non-little cell lung cancer are just as likely to display an epidermal growth factor receptor mutation in tumors as Caucasians, which implies they are as likely to reap the benefits of targeted therapies such as erlotinib iodine . ‘This study has immediate implications for patient management. Individuals with EGFR mutations possess a far greater prognosis and respond better to erlotinib than those who do not,’ said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer tumor Institute, and associate professor at Wayne State University School of Medicine.
Weiner says, The outcomes of the study show we have to learn more about the causes of parkinsonism and find ways to get over these disparities, which clearly are affecting the quality of life of individuals who are from different means and backgrounds. The distinctions in function between individuals with different education levels may suggest that patients with more education are perhaps more likely to demand a referral to an expert. Conversely, it’s possible that physicians are more likely to refer more extremely educated patients to an expert. The research team, which included staff and doctors from the University of Maryland Section of Neurology, Department of Psychiatry and Division of Epidemiology and Public Health, evaluated patients who found the Maryland Parkinson’s Disease and Movement Disorders Center over a five-year period.